XILLIX FDA APPROVED Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XILLIX FDA APPROVED

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Garth Richmond who wrote (330)	11/26/1998 6:54:00 PM
From: Robert Dydo	Read Replies (1) of 572

In the Nov. 27 issue, The Investment Reporter says Xillix (70 cents) is a buy for speculative patient, investors only. Many biotech stocks have been battered this year and Xillix is no exception. The stock declined over 60 per cent since the Reporter said buy at $1.85 in the June 26 issue. Yet clinical acceptance of the LIFE-Lung fluorescence endoscopy system which detects lung cancer at an early stage is progressing well, and is being sold by Olympus Optical of Tokyo. For the nine months to Sept. 30, 1998 Xillix lost $2.9-million against a loss of $3.8-million in 1997. Revenues rose 5.8 per cent to $3.6-million however, product sales rose 29 per cent, offsetting a decline in contract revenues. Xillix continues to receive contract revenue from Olympus to further develop a new device for the detection of gastrointestinal cancers. The Reporter says it should take a few years before Xillix becomes profitable, yet its product pipeline continues to grow as the company positions itself for feasibility studies of three new applications of its technology.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next